NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free TVGN Stock Alerts $0.99 0.00 (-0.07%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$0.99▼$1.0050-Day Range$0.85▼$7.8252-Week Range$0.80▼$21.09Volume29,945 shsAverage Volume427,852 shsMarket Capitalization$15.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Get Tevogen Bio alerts: Email Address Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About Tevogen Bio Stock (NASDAQ:TVGN)Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.Read More TVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVGN Stock News HeadlinesMay 1, 2024 | globenewswire.comTevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational ObjectivesApril 27, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.April 26, 2024 | globenewswire.comTevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 26, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.98%April 20, 2024 | morningstar.comTevogen Bio Holdings Inc TVGNApril 16, 2024 | msn.comLive Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionApril 11, 2024 | finance.yahoo.comTevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.April 11, 2024 | globenewswire.comTevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 5, 2024 | seekingalpha.comTVGN Tevogen Bio Holdings Inc.April 4, 2024 | investorplace.comWhy Is Tevogen Bio (TVGN) Stock Up 46% Today?April 3, 2024 | globenewswire.comTevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate DevelopmentMarch 28, 2024 | globenewswire.comTevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion PriceMarch 27, 2024 | globenewswire.comTevogen Bio Announces Series A-1 Preferred Stock InvestmentMarch 20, 2024 | businesswire.comTevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 VariantFebruary 27, 2024 | businesswire.comMittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AIFebruary 21, 2024 | businesswire.comCell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID TreatmentFebruary 17, 2024 | businesswire.comCell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open MarketFebruary 15, 2024 | businesswire.comTevogen Bio Announces $8 Million Equity InvestmentFebruary 14, 2024 | globenewswire.comTevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGNSee More Headlines Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CUSIPN/A CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-21.83% Return on Assets-0.28% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.90Miscellaneous Outstanding Shares15,820,000Free Float6,864,000Market Cap$15.67 million OptionableN/A Beta0.49 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Ryan H. Saadi M.D.M.P.H, M.P.H., Co-Founder, CEO & ChairmanMr. Kirti DesaiCFO & DirectorMr. Stephen Chen M.B.A.Chief Technical OfficerDr. Neal Flomenberg M.D.Chief Scientific Officer, Global R&D Lead & Chairman of Corporate BoardMr. Mittul MehtaChief Information Officer & Head of Tevogen.aiMr. Tapan V. ShahHead of Investor Relations & Corporate DevelopmentMr. Jeffrey Feike M.P.H.Chief Patient Officer, Member of Innovation & Public Health Advisory Council & DirectorMr. Sadiq KhanChief Commercial OfficerMore ExecutivesKey CompetitorsSenti BiosciencesNASDAQ:SNTICoeptis TherapeuticsNASDAQ:COEPPharmaCyte BiotechNASDAQ:PMCBAptose BiosciencesNASDAQ:APTOChromocell TherapeuticsNYSE:CHROView All Competitors TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed in 2024? Tevogen Bio's stock was trading at $9.51 on January 1st, 2024. Since then, TVGN stock has decreased by 89.6% and is now trading at $0.9898. View the best growth stocks for 2024 here. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVGN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressAI “wealth window” is closing June 25thParadigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
